Our data demonstrated a significant correlation between Th17 cells and AKT activation in situ and showed that cervical cancer patients with higher frequencies of Th17 cells and phosphorylated AKT expression scores in their tumor tissues showed a significantly lower response to CRT. This evidence concerns the gene AKT1 and cervical cancer.